Background: The evolution and spread of drug-resistant tuberculosis threatens to undermine TB control programs. Resistance in MTB arises through serial acquisition of point mutations in genes encoding drug-activating enzymes or drug targets. Current molecular diagnostics amplify and detect known drug resistance mutations, and their performance depends on identification of a comprehensive catalog of these loci. Although known mutations explain much resistance, mutations have not been identified in 10-40% of clinically resistant isolates. In addition to classical drug resistance genes (encoding the protein target of the drug or a drug-metabolizing enzyme), mutations in other classes of genes may confer a selective advantage in the presence of drugs. For example, mutations that reduce cell wall permeability or increase the activity of drug efflux pumps may increase the MICs of drugs, potentially providing an early step toward full-blown drug resistance. We developed methods to use whole genome sequences of MTB strains to identify biomarkers of drug resistance in a rapid unbiased manner. This approach identified 39 genetic loci newly associated with resistance, 5 of which were associated with cell wall permeability phenotypes. The unique mycobacterial cell wall contains unusual, complex lipids which contribute to the permeability barrier that underlies the intrinsic antibiotic resistance of most mycobacteria. Multiple tuberculosis drugs target cell wall structures, and many known resistance genes code for enzymes in cell wall lipid pathways. Two of the newly identified genes (murD and ponA1) contribute to the biosynthesis and homeostasis of the cell wall component peptidoglycan. Functional analysis of PonA1 mutants demonstrated an in vitro growth advantage in the presence of the drug rifampicin.
Conclusions: Three of the five genes (ppsA, pks12 and pks3) participate in the biosynthesis and translocation of surface-exposed lipids. Previous work showed that MICS are reduced in pks12-deficient M. avium and that targeted pks12 deletion in BCG leads to increased ethidium bromide uptake and antibiotic sensitivity. Recently, we used an unbiased metabolomics approach to analyze a set of progressively resistant strains from a human patient who developed high level drug resistance, identifying 96 molecules whose intensity changed coincident with the acquisition of resistance.Among these was the lipid product of Pks12, which increased consistent with a gain of function phenotype.